X
Details:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Mecce 2023
Not Confirmed
Contact Supplier
Details:
Abiraterone acetate is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.
Lead Product(s): Abiraterone Acetate
Therapeutic Area: Oncology Product Name: Abiraterone Acetate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2023
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Levosimendan (TNX-102 and TNX-103) is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action.
Lead Product(s): Levosimendan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TNX-102
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Tenax Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Mecce 2023
Not Confirmed
Contact SupplierDetails:
Nubeqa (darolutamide) is an oral androgen receptor inhibitor with a unique chemical structure developed to inhibit the growth of cancer cells. FDA has approved its use in combination with docetaxel for treating metastatic hormone-sensitive prostate cancer.
Lead Product(s): Darolutamide,Docetaxel
Therapeutic Area: Oncology Product Name: Nubeqa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Mecce 2023
Not Confirmed
Contact SupplierDetails:
ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Lead Product(s): ODM-208,Glucocorticoid,Fludrocortisone Acetate
Therapeutic Area: Oncology Product Name: ODM-208
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $290.0 million
Deal Type: Collaboration July 13, 2022
Mecce 2023
Not Confirmed
Contact SupplierDetails:
The research collaboration is based on new innovations that would improve the structure of the CAR T cell preparation. Cancer immunotherapy and one of its implementation methods, CAR T cell therapy, have brought completely new possibilities to cancer treatment.
Lead Product(s): CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Veripalvelu
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2022
Mecce 2023
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
